ZOLINZA vorinostat

Drug Class

Histone deacetylase inhibitor

Mechanism

Inhibits Class I and II HDACs, inducing histone accumulation of acetyl groups to cause chromatin remodeling and tumor cell apoptosis.

Approved Indication

Treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent or recurrent disease on or following two systemic therapies.

What This Means For Patients

ZOLINZA is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2006) — Sources

Pivotal Clinical Evidence

• Study 001 — Olsen et al., J Clin Oncol 2007 (NCT00097929) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021991s006lbl.pdf